Search Results - "Schwalbe, Ed C."

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease by Hill, Rebecca M., Kuijper, Sanne, Lindsey, Janet C., Petrie, Kevin, Schwalbe, Ed C., Barker, Karen, Boult, Jessica K.R., Williamson, Daniel, Ahmad, Zai, Hallsworth, Albert, Ryan, Sarra L., Poon, Evon, Robinson, Simon P., Ruddle, Ruth, Raynaud, Florence I., Howell, Louise, Kwok, Colin, Joshi, Abhijit, Nicholson, Sarah Leigh, Crosier, Stephen, Ellison, David W., Wharton, Stephen B., Robson, Keith, Michalski, Antony, Hargrave, Darren, Jacques, Thomas S., Pizer, Barry, Bailey, Simon, Swartling, Fredrik J., Weiss, William A., Chesler, Louis, Clifford, Steven C.

“…We undertook a comprehensive clinical and biological investigation of serial medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family…”
Get full text

TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours by Lindsey, Janet C., Schwalbe, Ed. C., Potluri, Sandeep, Bailey, Simon, Williamson, Daniel, Clifford, Steven C.

Get full text

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma by Ryan, Sarra L., Schwalbe, Ed C., Cole, Michael, Lu, Yuan, Lusher, Meryl E., Megahed, Hisham, O’Toole, Kieran, Nicholson, Sarah Leigh, Bognar, Laszlo, Garami, Miklos, Hauser, Peter, Korshunov, Andrey, Pfister, Stefan M., Williamson, Daniel, Taylor, Roger E., Ellison, David W., Bailey, Simon, Clifford, Steven C.

“…The MYC oncogenes are the most commonly amplified loci in medulloblastoma, and have previously been proposed as biomarkers of adverse disease prognosis by us…”
Get full text

Rapid Diagnosis of Medulloblastoma Molecular Subgroups by SCHWALBE, Ed C, LINDSEY, Janet C, ELLISON, David W, BAILEY, Simon, CLIFFORD, Steven C, STRAUGHTON, Debbie, HOGG, Twala L, COLE, Michael, MEGAHED, Hisham, RYAN, Sarra L, LUSHER, Meryl E, TAYLOR, Michael D, GILBERTSON, Richard J

“…Microarray studies indicate medulloblastoma comprises distinct molecular disease subgroups, which offer potential for improved clinical management. Minimal…”
Get full text

Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types by Schwalbe, Ed. C., Hayden, James T., Rogers, Hazel A., Miller, Suzanne, Lindsey, Janet C., Hill, Rebecca M., Nicholson, Sarah-Leigh, Kilday, John-Paul, Adamowicz-Brice, Martyna, Storer, Lisa, Jacques, Thomas S., Robson, Keith, Lowe, Jim, Williamson, Daniel, Grundy, Richard G., Bailey, Simon, Clifford, Steven C.

Get full text

TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas by Lindsey, Janet C, Hill, Rebecca M, Megahed, Hisham, Lusher, Meryl E, Schwalbe, Ed C, Cole, Michael, Hogg, Twala L, Gilbertson, Richard J, Ellison, David W, Bailey, Simon, Clifford, Steven C

Get full text

Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma by ZHUKOVA, Nataliya, RAMASWAMY, Vijay, VON BUEREN, André O, JONES, David T. W, NORTHCOTT, Paul A, KOOL, Marcel, STURM, Dominik, PUGH, Trevor J, POMEROY, Scott L, CHO, Yoon-Jae, PIETSCH, Torsten, GESSI, Marco, REMKE, Marc, RUTKOWSKI, Stefan, BOGNAR, Laszlo, KLEKNER, Almos, CHO, Byung-Kyu, KIM, Seung-Ki, WANG, Kyu-Chang, EBERHART, Charles G, FEVRE-MONTANGE, Michelle, FOULADI, Maryam, FRENCH, Pim J, PFAFF, Elke, KROS, Max, GRAJKOWSKA, Wieslawa A, GUPTA, Nalin, WEISS, William A, HAUSER, Peter, JABADO, Nada, JOUVET, Anne, SHIN JUNG, KUMABE, Toshihiro, LACH, Boleslaw, SHIH, David J. H, LEONARD, Jeffrey R, RUBIN, Joshua B, LIAU, Linda M, MASSIMI, Luca, POLLACK, Ian F, YOUNG SHIN RA, VAN MEIR, Erwin G, ZITTERBART, Karel, SCHÜLLER, Ulrich, HILL, Rebecca M, MARTIN, Dianna C, LINDSEY, Janet C, SCHWALBE, Ed C, BAILEY, Simon, ELLISON, David W, HAWKINS, Cynthia, MALKIN, David, CLIFFORD, Steven C, KORSHUNOV, Andrey, PFISTER, Stefan, TAYLOR, Michael D, CASTELO-BRANCO, Pedro, BASKIN, Berivan, RAY, Peter N, BOUFFET, Eric

“…Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through the inclusion of…”
Get full text

Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome by Kolodziejczak, Anna S, Guerrini-Rousseau, Lea, Planchon, Julien Masliah, Ecker, Jonas, Selt, Florian, Mynarek, Martin, Obrecht, Denise, Sill, Martin, Autry, Robert J, Stutheit-Zhao, Eric, Hirsch, Steffen, Amouyal, Elsa, Dufour, Christelle, Ayrault, Olivier, Torrejon, Jacob, Waszak, Sebastian M, Ramaswamy, Vijay, Pentikainen, Virve, Demir, Haci Ahmet, Clifford, Steven C, Schwalbe, Ed C, Massimi, Luca, Snuderl, Matija, Galbraith, Kristyn, Karajannis, Matthias A, Hill, Katherine, Li, Bryan K, Walsh, Mike, White, Christine L, Redmond, Shelagh, Loizos, Loizou, Jakob, Marcus, Kordes, Uwe R, Schmid, Irene, Hauer, Julia, Blattmann, Claudia, Filippidou, Maria, Piccolo, Gianluca, Scheurlen, Wolfram, Farrag, Ahmed, Grund, Kerstin, Sutter, Christian, Pietsch, Torsten, Frank, Stephan, Schewe, Denis M, Malkin, David, Ben-Arush, Myriam, Sehested, Astrid, Wong, Tai-Tong, Wu, Kuo-Sheng, Liu, Yen-Lin, Carceller, Fernando, Mueller, Sabine, Stoller, Schuyler, Taylor, Michael D, Tabori, Uri, Bouffet, Eric, Kool, Marcel, Sahm, Felix, von Deimling, Andreas, Korshunov, Andrey, von Hoff, Katja, Kratz, Christian P, Sturm, Dominik, Jones, David T W, Rutkowski, Stefan, van Tilburg, Cornelis M, Witt, Olaf, Bougeard, Gaëlle, Pajtler, Kristian W, Pfister, Stefan M, Bourdeaut, Franck, Milde, Till

“…Abstract Background The prognosis for Li–Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group…”
Get full text

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial by Clifford, Steven C, Lannering, Birgitta, Schwalbe, Ed C, Hicks, Debbie, O'Toole, Kieran, Nicholson, Sarah Leigh, Goschzik, Tobias, Zur Mühlen, Anja, Figarella-Branger, Dominique, Doz, François, Rutkowski, Stefan, Gustafsson, Göran, Pietsch, Torsten

“…To improve stratification of risk-adapted treatment for non-metastatic (M0), standard-risk medulloblastoma patients by prospective evaluation of biomarkers of…”
Get full text

Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death by Rogers, Hazel A., Kilday, John-Paul, Mayne, Cerys, Ward, Jennifer, Adamowicz-Brice, Martyna, Schwalbe, Ed C., Clifford, Steven C., Coyle, Beth, Grundy, Richard G.

“…Epigenetic alterations, including methylation, have been shown to be an important mechanism of gene silencing in cancer. Ependymoma has been well characterized…”
Get full text

Genome-Wide Analysis of Alternative Splicing in Medulloblastoma Identifies Splicing Patterns Characteristic of Normal Cerebellar Development by MENGHI, Francesca, JACQUES, Thomas S, BARENCO, Martino, SCHWALBE, Ed C, CLIFFORD, Steven C, HUBANK, Mike, HAM, Jonathan

“…Alternative splicing is an important mechanism for the generation of protein diversity at a post-transcriptional level. Modifications in the splicing patterns…”
Get full text

Abstract LB-324: A whole chromosome aberration phenotype in non-WNT/non-SHH tumors predicts outcome within standard-risk medulloblastomas from the HIT-SIOP-PNET4 clinical trial by Goschzik, Tobias, Schwalbe, Ed C., Hicks, Debbie, Figarella-Branger, Dominique, Doz, Francois, Rutkowski, Stefan, Gustafsson, Goran, Lannering, Birgitta, Pietsch, Torsten, Clifford, Steve C.

“…Abstract Introduction: Standard-risk medulloblastoma (SR-MB; 50-60% of patients) is currently defined by the absence of high-risk (e.g. metastatic disease,…”
Get full text

MBRS-29. IN-VIVO METABOLITE PROFILES FOR THE NON-INVASIVE AND RAPID IDENTIFICATION OF MOLECULAR SUBGROUP IN MEDULLOBLASTOMA by Kohe, Sarah E, Babourina-Brooks, Ben, Scerif, Fatma, Hicks, Debbie, Schwalbe, Ed C, Crosier, Stephen, Lindsey, Janet, Adiamah, Magretta, Storer, Lisa C D, Lourdusamy, Anbarasu, Gill, Simrandip K, Bennett, Christopher D, Wilson, Martin, Avula, Shivaram, Mitra, Dipayan, Dineen, Rob, Bailey, Simon, Williamson, Daniel, Grundy, Richard G, Clifford, Steven C, Peet, Andrew C

“…Abstract Molecular subgroup is now influencing risk stratification and disease management in medulloblastoma. Tissue metabolite profiles have shown promise in…”
Get full text

Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance by Lindsey, J C, Kawauchi, D, Schwalbe, E C, Solecki, D J, Selby, M P, McKinnon, P J, Olson, J M, Hayden, J T, Grundy, R G, Ellison, D W, Williamson, D, Bailey, S, Roussel, M F, Clifford, S C

“…The identification of key tumorigenic events in Sonic Hedgehog (SHH) subgroup medulloblastomas (MB SHH ) will be essential for the development of…”
Get full text

MB-84IDENTIFICATION OF MEDULLOBLASTOMA MOLECULAR SUBGROUPS USING METABOLITE PROFILES by Kohe, Sarah, Gill, Simrandip K., Hicks, Debbie, Schwalbe, Ed C., Crosier, Stephen, Storer, Lisa, Lourdusamy, Anbarasu, Bennett, Christopher D., Wilson, Martin, Bailey, Simon, Williamson, Daniel, Grundy, Richard G., Clifford, Steven C., Peet, Andrew C.

Get full text

Abstract LB-201: MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically by Hill, Rebecca M., Kuijper, Sanne, Lindsey, Janet, Schwalbe, Ed C., Barker, Karen, Boult, Jessica, Williamson, Daniel, Ahmad, Zai, Hallsworth, Albert, Ryan, Sarra, Poon, Evon, Robinson, Simon, Ruddle, Ruth, Raynaud, Florence, Howell, Louise, Kwok, Colin, Joshi, Abhijit, Nicholson, Sarah, Crosier, Stephen, Wharton, Stephen, Jacques, Tom, Robson, Keith, Michalski, Antony, Hargrave, Darren, Pizer, Barry, Bailey, Simon, Swartling, Fredrik J., Petrie, Kevin, Weiss, William A., Chesler, Louis, Clifford, Steve

“…Abstract Disease recurrence following multi-modal therapy is the single most adverse event in medulloblastoma (MB). Currently >90% of relapsing patients die,…”
Get full text

MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically by Hill, Rebecca M., Kuijper, Sanne, Lindsey, Janet, Schwalbe, Ed C., Barker, Karen, Boult, Jessica, Williamson, Daniel, Ahmad, Zai, Hallsworth, Albert, Ryan, Sarra, Poon, Evon, Robinson, Simon, Ruddle, Ruth, Raynaud, Florence, Howell, Louise, Kwok, Colin, Joshi, Abhijit, Nicholson, Sarah, Crosier, Stephen, Wharton, Stephen, Jacques, Tom, Robson, Keith, Michalski, Antony, Hargrave, Darren, Pizer, Barry, Bailey, Simon, Swartling, Fredrik J., Petrie, Kevin, Weiss, William A., Chesler, Louis, Clifford, Steve

Get full text

Abstract 3442: TP53 mutations in favorable risk WNT subtype medulloblastomas by Hill, Rebecca M., Lindsey, Janet C., Megahed, Hisham, Schwalbe, Ed C., Cole, Michael, Hogg, Twala L., Gilbertson, Richard J., Ellison, David W., Bailey, Simon, Clifford, Steven C.

“…Abstract Medulloblastoma (MB) is the most common malignant brain tumor of childhood. Although overall cure rates of ∼70% are now achieved, advances in our…”
Get full text

Abstract 3449: Epigenomics identifies conserved DNA methylation events associated with medulloblastoma development in humans and mice by Lindsey, Janet C., Schwalbe, Ed C., Kawauchi, Daisuke, Olson, Jim M., McKinnon, Peter J., Gilbertson, Richard J., Roussel, Martine F., Ellison, David W., Bailey, Simon, Clifford, Steven C.

“…Abstract Medulloblastoma, an invasive embryonal tumor of the cerebellum, is the most common malignant brain tumor of childhood. Genome-wide technologies have…”
Get full text